# US 2009/0275618 A1 · 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as cb1 receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0275618 A1
- Document ID: US20090275618A1
- Status: Published application
- Kind: A1
- Application number: 12/441,570
- Filed: 2007-10-22
- Published: 2009-11-05
- Earliest claimed: 2006-10-23
- Assignees: Eli Lilly and Company
- Inventors: David Scott Coffey; Jingdan Hu; Stacy Jo Keding; Joseph Herman Krushinski, JR.; John Mehnert Schaus; David Edward Tupper
- Web page: https://patentgrep.com/patent/US20090275618A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/38: 2-Pyrrolones
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB1 receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.

## Claims

### Claim 1

A compound of Formula
wherein:
R1 is selected from the group consisting of:
a) —H,
b) halo,
c) —OCF3,
d) —OCH3,
e) methyl,
f)—SO2CH3,
g) —CF3, and
h)—CN;
R2 is at least one substituent independently selected from the group consisting of:
a) —H,
b) halo,
c) —CF3,
d) —(C1-C4) alkyl,
e) cyclopropyl,
f) —O-cyclopropyl,
g) —SCF3,
h) —OCF3
i) —OCH2CF3,
j) —CN, and
k) —O—(C1-C3)alkyl;
R3 is at least one substituent independently selected from selected from the group consisting of:
a) —H,
b) —CF3,
c) —(C1-C4) alkyl,
d) cyclopropyl,
e) —OCH3,
f) halo, and
g) phenyl;
each R4 and R5 is independently selected from the group consisting of H, methyl, and ethyl, or both R4 and R5 may be taken together with the carbon to which each is attached to form a cyclopropyl ring; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 having the Formula
wherein:
R1 is selected from the group consisting of:
a) —H,
b) halo,
c) —OCF3,
d) —OCHF2,
e) —OCH3,
f) methyl,
g) isopropyl,
h) cyclopropyl,
i) —CF3, and
j) —CN;
R2 is one or two substituents independently selected from the group consisting of:
a) —O-cyclopropyl,
b) —SCF3,
c) —OCF3,
d) —OCHF2,
e) —OCH2CF3, and
f) —OCF2CF2H;
R3 is selected from:
a) —CF3, or
b) -cyclopropyl;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2
wherein:
R1 is selected from the group consisting of:
a) —OCF3 and
b) —OCHF2;
R2 is one or two substituents independently selected from the group consisting of:
a) —H,
b) halo,
c) -fluorosubstitued (C1-C3)alkyl,
d) —(C1-C4) alkyl, and
e) —CN;
R3 is selected from the group consisting of:
a) —CF3,
b) -cyclopropyl, and
c) halo;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 2)

The compound of claim 2, having the Formula
wherein:
R1 is selected from the group consisting of:
a) —H,
b) halo,
c) —OCF3,
d) —OCHF2,
e) —OCH3,
f) methyl,
g) isopropyl,
h) cyclopropyl,
i) —CF3, and
j) —CN;
R2 is one or two substituents independently selected from the group consisting of:
a) —O-cyclopropyl,
b) —SCF3,
c) —OCF3,
d) —OCHF2,
e) —OCH2CF3, and
f) —OCF2CF2H;
R3 is selected from:
a) —CF3, or
b) -cyclopropyl;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 2)

The compound of claim 2, having the Formula
wherein:
R1 is selected from the group consisting of:
a) —H,
b) halo,
c) —OCF3,
d) —OCHF2,
e) —OCH3,
f) methyl,
g) isopropyl,
h) cyclopropyl,
i) —CF3, and
j) —CN;
R2 is one or two substituents independently selected from the group consisting of:
a) —O-cyclopropyl,
b) —SCF3,
c) —OCF3,
d) —OCHF2,
e) —OCH2CF3, and
f) —OCF2CF2H;
R3 is selected from:
a) —CF3, or
b) -cyclopropyl;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 3)

The compound of claim 3, having Formula
wherein:
R1 is selected from the group consisting of:
a) —OCF3 and
b) —OCHF2;
R2 is one or two substituents independently selected from the group consisting of:
a. —H,
b. halo,
c. -fluorosubstitued (C1-C3) alkyl,
d. —(C1-C4) alkyl, and
e. —CN;
R3 is selected from the group consisting of:
a) —CF3,
b) -cyclopropyl, and
c) halo;
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 3)

The compound of claim 3, having the Formula
wherein:
R1 is selected from the group consisting of:
a) —OCF3 and
b) —OCHF2;
R2 is one or two substituents independently selected from the group consisting of:
a) —H,
b) halo,
c) -fluorosubstitued (C1-C3) alkyl,
d) —(C1-C4) alkyl, and
e) —CN;
R3 is selected from the group consisting of:
a) —CF3,
b) -cyclopropyl, and
c) halo;
or a pharmaceutically acceptable salt thereof.

### Claim 8

A compound of Formula

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim at position 10

-14. (canceled)

### Claim 15 (depends on 1)

A method of treating a condition, wherein the condition is obesity, schizophrenia, cognitive impairment associated with schizophrenia, substance abuse or alcohol dependence, smoking cessation, or treatment emergent weight gain observed during smoking cessation, in a mammal comprising administering to the mammal an effective amount of a compound claim 1, or a pharmaceutically acceptable salt thereof, in simultaneous, separate, or sequential combination with an antipsychotic agent.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The method of claim 15, wherein the condition is obesity.

### Claim 18 (depends on 15)

The method of claim 15, wherein the condition is schizophrenia.

### Claim 19 (depends on 15)

The method of claim 15, wherein the condition is cognitive impairment associated with schizophrenia.

### Claim 20 (depends on 15)

The method of claim 15 wherein the condition is substance abuse or alcohol dependence.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A method of treating a condition, wherein the condition is schizophrenia, weight gain, obesity, cognitive impairment associated with schizophrenia, substance abuse or alcohol dependence, smoking cessation, or treatment emergent weight gain observed during treatment with an atypical antipsychotic, in a mammal comprising administering to the mammal an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the condition is schizophrenia.

### Claim 25 (depends on 23)

The method of claim 23, wherein the condition is weight gain.

### Claim 26 (depends on 23)

The method of claim 23, wherein the condition is obesity.

### Claim 27 (depends on 23)

The method of claim 23, wherein the condition is cognitive impairment associated with schizophrenia.

### Claim 28 (depends on 23)

The method of claim 23, wherein the condition is substance abuse or alcohol dependence.

### Claim 29

(canceled)

### Claim 30

(canceled)
